Free Trial
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Collegium Pharmaceutical logo
$35.54 -0.08 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$35.52 -0.02 (-0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Collegium Pharmaceutical Stock (NASDAQ:COLL)

Advanced

Key Stats

Today's Range
$35.44
$36.56
50-Day Range
$29.75
$39.59
52-Week Range
$23.23
$42.29
Volume
305,798 shs
Average Volume
377,734 shs
Market Capitalization
$1.12 billion
P/E Ratio
34.17
Dividend Yield
N/A
Price Target
$42.33
Consensus Rating
Buy

Company Overview

Collegium Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

COLL MarketRank™: 

Collegium Pharmaceutical scored higher than 81% of companies evaluated by MarketBeat, and ranked 225th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Collegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Collegium Pharmaceutical has a consensus price target of $42.33, representing about 18.6% upside from its current price of $35.69.

  • Amount of Analyst Coverage

    Collegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Collegium Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Collegium Pharmaceutical is 34.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Collegium Pharmaceutical is 34.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.03.

  • Price to Book Value per Share Ratio

    Collegium Pharmaceutical has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Collegium Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    14.16% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 2.26%, indicating that investor sentiment is improving.
  • Dividend Yield

    Collegium Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    Collegium Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.16% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 2.26%, indicating that investor sentiment is improving.
  • News Sentiment

    Collegium Pharmaceutical has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Collegium Pharmaceutical this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,084,207.00 in company stock.

  • Percentage Held by Insiders

    Only 2.51% of the stock of Collegium Pharmaceutical is held by insiders.

  • Read more about Collegium Pharmaceutical's insider trading history.
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COLL Stock News Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More Headlines

COLL Stock Analysis - Frequently Asked Questions

Collegium Pharmaceutical's stock was trading at $28.65 at the beginning of the year. Since then, COLL stock has increased by 24.6% and is now trading at $35.69.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by $0.01. The firm's quarterly revenue was up 22.7% compared to the same quarter last year.
Read the conference call transcript
.

Collegium Pharmaceutical's board authorized a share repurchase plan on Monday, July 7th 2025, which allows the company to buy back $150,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 15.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Top institutional investors of Collegium Pharmaceutical include Rubric Capital Management LP (10.02%), Eventide Asset Management LLC (8.39%), Invesco Ltd. (5.03%) and Emerald Advisers LLC (2.61%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Scott Dreyer, Gino Santini, Thomas B Smith, Garen G Bohlin, Michael Thomas Heffernan and John Gordon Freund.
View institutional ownership trends
.

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
9/17/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COLL
CIK
1267565
Fax
N/A
Employees
210
Year Founded
2002

Price Target and Rating

High Price Target
$46.00
Low Price Target
$37.00
Potential Upside/Downside
+16.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.04
Trailing P/E Ratio
34.87
Forward P/E Ratio
6.46
P/E Growth
N/A
Net Income
$69.19 million
Net Margins
5.13%
Pretax Margin
7.50%
Return on Equity
97.28%
Return on Assets
13.87%

Debt

Debt-to-Equity Ratio
3.27
Current Ratio
1.18
Quick Ratio
1.10

Sales & Book Value

Annual Sales
$631.45 million
Price / Sales
1.81
Cash Flow
$12.82 per share
Price / Cash Flow
2.83
Book Value
$7.10 per share
Price / Book
5.11

Miscellaneous

Outstanding Shares
31,500,000
Free Float
30,711,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
0.63

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:COLL) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners